According to results of a multicenter randomized clinical trial, patients with advanced NSCLC derived no benefit from the addition of sorafenib (Nexavar) to chemotherapy.

References and Resources
Scagliotti G et al. “Sorafenib plus carboplatin/paclitaxel in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC): interim analysis (IA) results from the phase III, randomized, double-blind, placebo-controlled, trial. ELCC. 2008; Abstract 6. (ahead of print)

Sponsored by The Doctor’s Channel